broadAdmin – Best Small Cap Stock Picks Best Small Cap Stocks to Trade

May 07 2020

Hot sector, Golden cross chart. Technology for the Future of Healthcare (NASDAQ: VUZI)

VUZI Has Tools for the Future of Healthcare

Golden cross formation on the chart, Oversold, Low float, Tele-medicine & wearable tech are both HOT sectors

Good day everyone,

We are initiating coverage of Vuzix Corporation (NASDAQ: VUZI), a company that designs, manufactures, markets, and sells augmented reality (AR) wearable display and computing devices.

Current price $1.75 per share
Outstanding (est.) 33.1 million shares
Float (est.) 27.4 million shares
% Held by Insiders and Institutions approx. 28%
Cash on hand most recent quarter $10.61M
52-week range $.86 to $5.00

We have been watching VUZI shares for a while and feel like right now could be the time to talk about the shares given the current price. After bottoming out in mid-March, VUZI shares have gained some traction, eclipsing their 50 DMA of $1.41 and closing in on their 200 DMA of $1.95. A break past $1.95 may create a catalyst for the company shares to seek a new, higher resistance level.

Trading volumes were strong through April and the shares are leading their SMA 20, both potential indicators of trending shares.

VUZI shares are trading 65% off their 52-week high.

11.9% of the outstanding shares are held by insiders and 15.3% are held by institutions. Insiders with a vested interest in the company and institutions with professionals in tech investments.

Recent analysts target:
3/19/2020 Maxim Group Reiterated Rating Buy $3.50

Vuzix AR wearable display devices are worn like eyeglasses or attach to a head worn mount to view, record, and interact with video and digital content, such as computer data, the Internet, social media, and entertainment applications.

On May 5th, the company announced it has received a replenishment order for M400 Smart Glasses orders from Gemvision to support their efforts to meet COVID-19 remote healthcare needs in the Netherlands.

Two weeks ago, VUZI announced the commercial availability of a turnkey M400 Smart Glasses Remote Worker Connectivity Bundle powered by Sprint Curiosity™ IoT. The new connectivity bundle can offer COVID-19 tele-medicine support in rural hospitals, nursing homes and other remote medical facilities.

Remote healthcare and tele-medicine are the wave of the future. Many of us have already experienced tele-medicine during the Covid 19 pandemic as clinics and doctor’s offices remain somewhat closed.

By utilizing smart-glasses, nurses, EMTs and other front line healthcare providers could call and consult with a doctor while keeping their hands free to perform any treatment.

Wounds can be verbally described, but that is difficult. When a physician can view a wound, it helps greatly. The view of a patient seen by a medical professional wearing smart-glasses could be immediately shared with other members of the care team.

Patients with transmissible diseases, such as Covid 19, could be physically seen by fewer medical professionals, reducing the incidence of transmission, and reducing costs at the same time.

As we all begin to visualize what the world may look like after the Covid 19 pandemic, tele-medicine could play a regular role in healthcare. We believe VUZI could be at the forefront of that new paradigm and we believe the investment community may be evaluating that inevitability as the trend in VUZI shares indicates.

As part of your due diligence you should read this press release: https://finance.yahoo.com/news/telemedicine-usage-vuzix-m400-smart-151100219.html

VUZI offers extraordinary technology, offering benefit to the way we work and live. It is within our nature to resist wearing any kind of extraneous product on our heads (think of face masks). That aversion may be going by the wayside as we realize the benefits of minimal contact in today’s world.

In March, while addressing the current health crisis, the company stated, “there has never been a better time to work hands-free and remotely with AR smart glasses than today.”

The displays (glasses) VUZI sells can be engineered for the industries they partner with. Some partners VUZI has worked with include:

US Department of Defense
Verizon
Qualcomm
Tellus
Sprint

The VUZI intellectual property portfolio consists of over 150 patents.

VUZIX utilizes Waveguide technology. Waveguides are thin (about 1 mm), transparent, optical elements that take a projected virtual image and relay it to the eye while expanding the exit pupil (viewing window) at the same time. Waveguides are transparent, so the smart glasses do not need to be removed to complete other tasks. This is the technology that sets VUZI apart from the competition.

In a significant development, the company recently announced that their M400 Smart Glasses are now supported by Bitnamic, a German-based software company that develops smart services for remote service, inspection, and maintenance of highly complex machines. If the technician wears Vuzix M400 Smart Glasses during the live broadcast, there is no need to look at a smartphone or tablet.

Products
Vuzix Blade Smart-glasses – Blade is a new way to use smart glasses. Waveguide optics project a see-through image to the user. These advanced optics do not obstruct regular vision and allow the user to perfectly switch between the digital world and reality. Sold in two models.

M-Series Smart-glasses – The Vuzix M-Series boasts the new M400 and cost-effective M300XL. Both models are rich in features, including nHD color displays, voice control, touchpad navigation, three axis gyroscope integrated head-tracking, 64GB internal flash memory, and left or right eye use.

Vuzix Labs Smart Swim – Smart Swim™ is a head-up display for swimmers, providing workout status and information about their swim. This enables users to continue uninterrupted and reach optimum performance.

Vuzix Remote Assist – Vuzix Remote Assist (VRA) is a streaming video app optimized for the growing lineup of Vuzix Smart Glasses. VRA increases productivity and customer satisfaction by sharing information between field technicians and remote support experts.

VUZIX also sells a complete line of accessories, apps, and merchandise.

VUZI shares are closing in on their 200-day moving average of $1.95 per share after crossing their 50 DMA last month. A break past these moving averages can mean the shares are ready to find a new, higher resistance level. Recent gains have caused VUZI shares to lead their SMA 20 by 10.9%.

VUZI Chart – https://stockcharts.com/h-sc/ui?s=vuzi

VUZI, as a leader in smart-glasses technology, could be at the forefront of a worldwide trend. Their continuing improvement in their products may expand the markets available to them. We believe their shares may reflect that status in the near term.

The Team

__________________________________________________

Your Consent

By using our site, you consent to our online privacy policy and disclaimer.

Do we disclose any information to outside parties?

We hate spam and we do not sell, trade, or otherwise transfer to outside parties your personally identifiable information.

What information do we collect?

We collect information from you when you subscribe to our newsletter or fill out a form. This includes your email address only.

When registering on our site, as appropriate, you may be asked to enter your: e-mail address

What do we use your information for?

When we collect your email it is used for one purpose to send you the free information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.

Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.

We send periodic emails

The email address you provide may be used to send you information, respond to inquiries, and/or other requests or questions.

How do we protect your information?

We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use a secure third party to send email to you.

Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act. We therefore will not distribute your personal information to outside parties without your consent.

Online Privacy Policy Only

This online privacy policy applies only to information collected through our website and not to information collected offline.

Contacting Us

If there are any questions regarding this privacy policy or disclaimer you may reply to this email.

DISCLAIMER

This website/newsletter is a wholly owned subsidiary of Small Cap Specialists LLC, herein referred to as SCS LLC.

Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.

PLEASE NOTE WELL: SCS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold SCS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. SCS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SCS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead SCS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. SCS LLC is compliant with the Can Spam Act of 2003. SCS LLC does not offer such advice or analysis, and SCS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.

The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.

In preparing this publication, SCS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. SCS LLC has been compensate.d fifteen thousand dollars cash via bank wir.e by venado media llc for this weeks coverage of vuzi. The advertisements in this website are believed to be reliable, however, SCS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. SCS LLC is not responsible for any claims made by the companies advertised herein, nor is SCS LLC responsible for any other promotional firm, its program or its structure.
SCS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA.

May 01 2020

Join Broad Street Alerts Facebook Group “Small Cap Breakout Stocks”

https://www.facebook.com/groups/975773535841394/

The Team Invites You!

____________________________________________________________________

DISCLAIMER

This website/newsletter is a wholly owned subsidiary of Small Cap Specialists LLC, herein referred to as SCS LLC.

PLEASE NOTE WELL: SCS LLC and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold SCS LLC, its operator’s owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. SCS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SCS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead SCS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. SCS LLC is compliant with the Can Spam Act of 2003. SCS LLC does not offer such advice or analysis, and SCS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries and extremely high degree of risk. It is possible that an investor’s investment may be lost or impaired due to the speculative nature of the companies profiled.

The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects”, “foresee”, “expects”, “will”, “anticipates”, “estimates”, “believes”, “understands”, or that by statements indicating certain actions & quote; “may”, “could”, or “might” occur. Understand there is no guarantee past performance will be indicative of future results.

In preparing this publication, SCS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The advertisements in this website are believed to be reliable, however, SCS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. SCS LLC is not responsible for any claims made by the companies advertised herein, nor is SCS LLC responsible for any other promotional firm, its program or its structure.
SCS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA.

Apr 18 2017

Why Should You Follow Broad Street Alerts?

Simple, our track record speaks for itself…

There are Big Opportunities for the Short and Long Term Trader in Small Cap’s

Broad Street Alerts recent profiles in 2017 and track record, 534% in verifiable potential gains for our members on 3 small cap alerts alone!

January 31st, 2017- (NASDAQ: HIMX) opened at $5.10/share and hit a high of $9.68/share March 24th, 2017 for gains of 89% within 60 days-

February 6th, 2017- (NASDAQ: SCON) opened at $1.12/share hit a high of $1.80/share within 10 days our member potential gains- 60% –

March 6th, 2017- (OTC: USRM) opened at .035/share and hit over .17/share within 25 days for gains of 385% for our members-

These are numbers that make traders drool. Any trader in any market would fall all over themselves to see numbers like this. So, if you’ve been on the fence, perhaps it’s time to start doing some research and verify our numbers for yourself. We are constantly raising the bar and separate ourselves from the rest of the small-cap newsletters as the best in business.

We know with a large following comes a large responsibility as we have everyone from institutional investors to the beginner following our profiled securities in our newsletters. This is something we take very seriously always seeking small cap growth companies that have both near and long-term potential for our members.

We do the hard work for you

Most investors don’t have time to track all the companies and do the in depth research and analysis necessary to make solid choices. We do the work for you… because that is our business.

Our picks are solid, real companies

Yes, they’re real businesses with revenues and assets, and real people behind them. Our picks represent real market and business growth potential…not wishes and pipe dreams.

***Get our small cap profiles, special situation and watch alerts in real time. We are now offering our VIP – SMS/text alert service for free, simply text the word “Alerts” to the phone number “25827” from your cell phone***

Apr 12 2017

What Happened to Valeant Pharmaceuticals?

It is interesting to see what is happening to Valeant Pharmaceuticals Intl Inc. (NYSE: VRX) ever since activist investor Bill Ackman announced that he had gotten rid of his stake in the pharmaceutical giant from Canada at a loss amounting to reportedly USD $ 2.8 billion or possibly even more. Bill Ackman’s Pershing Square Capital Management was the largest individual shareholder in the company spending an inordinate amount of time on a vast and expensive, highly publicised campaign to rejuvenate the stock price, which had declined by more than 90% since the commencement of the investment in the company. Mr Ackman pointed out the failed nature of the company business model, in which acquired assets were financed through borrowing, and success relied on product price increases before generics cut into market share. Since selling the stake, Ackman has been a strong critic of strategic errors from former CEO Michael Pearson and now feels that the time and effort required to revive and revitalized company may not be worth it.

What is wrong at Valeant

Mr. Pearson may be gone but investors were disappointed earlier this month when news broke that current CEO Joseph Papa took home a combined $62.7 million. This included a base salary of $980,769 a bonus worth $9.125 million and stocks and options worth nearly $52 million.

This was while Valeant’s stock lost nearly 62% of its value over the past year.

As at the end of December 2016, the company had $ 30 billion in debt balance by only $ 2 billion in operating cash flow and $ 3 billion in equity. At first glance, it would appear that the company will be unable to handle its debt problems and return value to investors. Most of the smart professional fund managers have fled the stock. While not following these professionals blindly, it is important to see how they act, especially if they have money in the game which they risk losing. Until recently, the stock was owned by most of the big hedge funds. The Sequoria Fund sold its stake, which costs the fund, $ 1 billion and ended the long career of manager Robert Goldfarb. Now Bill Ackman, till recently the biggest defender off the company, sold his stake acquired at an average of $ 196 a share for around $ 11 a share and the resulting loss of $ 2.8 billion is one of the biggest losses in the history of hedge funds. It looks as if fund managers have decided to sell to recover whatever money they can and only a few of the faithful, such as John Paulson remain.

____________________________________________________________________

_____________________________________________________________________

Investors should worry because Jim Chanos is arguably one of the most famous short sellers and contrarian investors and is reportedly short on the stock. He has shown a talent for finding problems in regulatory findings overlooked by many other investors and is famous for shorting stocks at their peak at a time when they are loved by Wall Street. Eventually, of course, the reality catches up, the stock price drops and Chanos takes his profits. He has compared this company with Enron at a time when the stock was a darling of Wall Street. He started shorting VRX when it is trading at $ 100 per share, noting that the lack of organic growth, the acquisition spree and aggressive accounting policies made him unhappy. Under previous CEO Michael Pearson, VRX did little drug research with R&D spending only around 3% of sales. Instead of the norm of 15% to 20%. Instead, the company would pile on debt to buy existing pharma companies and show profitability by reducing R&D spending and raising the prices of the acquired drugs.

Many people disliked the controversial strategy, including politicians who got the Senate to summon the company to Capitol Hill to question them about drug pricing. Long time Warren Buffett associate Charlie Munger accused the company of robbing hospitals. The company then promised to cut prices, even though some hospitals complained that they had achieved no cost savings. Moreover, a criminal probe was opened last year into the company and its relationship with Philidor the company in the mail order pharmacy business.

The financial problems

The growth by acquisition financed by large amounts of borrowing left it with a humongous amount of debt of around $ 30 billion. In contrast, the market capitalisation is only $ 3.71 billion and the revenue last year was only $ 9.67 billion. Metrics such as debt to equity of 9.47 and operating cash flow to that of 0.0699 do not look impressive. Moreover, the company made the inexplicable decision to take on a further $ 10 billion in debt as its stock price reached a high of $ 200 a share in March 2015. Prudence would have dictated an equity offering at high stock prices instead of additional debt. Twice last year, the company had to strike deals with creditors to relax the terms of its debt covenants and one third of the $ 10 billion in debt is floating rate borrowing. In an era where interest rates are expected to rise, an additional 100 basis points in interest rates will increase the interest bill by another $ 100 million.

Conclusion

While VRX stock has certainly disappointed many hedge fund and individual investors with a monumental stock price fall, and a bleak looking financial future, it should be noted: the VRX product pipeline has many products including household names like Bausch & Lomb and Wellbutrin. The current stock price is near a 9-year low and close to its book value. Annual revenues are still almost $10 billion and as recently as March 23, 2017, RBC Capital Markets issued a “sector perform” rating with a target of $18-23. The company was founded in 1983 and is headquartered in Laval, Canada.

Source: Broad Street Alerts Editor

About Broad Street Alerts

Big Opportunities in Small Cap’s

Broad Street Alerts recent profiles and track record, 534% in verifiable potential gains for our members on 3 small cap alerts alone!

January 31st, 2017- (NASDAQ: HIMX) opened at $5.10/share and hit a high of $9.68/share March 24th, 2017 for gains of 89% within 60 days-

February 6th, 2017- (NASDAQ: SCON) opened at $1.12/share hit a high of $1.80/share within 10 days our member potential gains- 60% –

March 6th, 2017- (OTC: USRM) opened at .035/share and hit over .17/share within 25 days for gains of 385% for our members-

Apr 11 2017

Is There a Path to Profitability for Novavax

Novavax, Inc. (NASDAQ: NVAX), a clinical-stage vaccine company, focuses on the discovery and development of recombinant nanoparticle vaccines and adjuvants. Through its recombinant nanoparticle vaccine technology, it produces vaccine candidates to treat both known and newly emerging diseases. The product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza, and the Ebola virus (EBOV). The lead adjuvant for human applications, Matrix-M, is in clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).

The share price of the company continued to decline downwards in March and fell some 15% and this decline appears to be the cause of the lack of clinical data and the expected cash burn rate. In the middle of September, the company had shocked and stunned investors after announcing that phase 3 trial (RESOLVE) of RSV F vaccine as a treatment for respiratory syncytial virus (RSV) in adults ages 60 and up had failed to meet its primary endpoint. The study also listed the secondary endpoint and did not show the requisite efficacy of the vaccine. Shares fell by more than 80% following this announcement and have yet to recover. The company is not giving up on the RSV vaccine and is continuing to run the phase 3 trial to prevent RSV in infants through the process of maternal immunization. It is also trying once again with older adults in a phase 2 trial with one and two formulations of doses, both with and without adjuvants. Clearly, it will take some time for additional data to emerge.

__________________________________________________________________

___________________________________________________________________

The bigger worry for investors is the rate at which the company is burning cash. At the end of 2016, the company had $ 234.5 million in cash and cash equivalents and, while this might sound adequate, it burnt more than $ 255 million in net cash in its operating activities last year. Even though the cash burn is likely to reduce with the completion of the RESOLVE trial involving 12,000 people, the quarters ahead are likely to see the company facing other large costs, leading to potential concerns about funding. A large part of the company’s future hinges on the PREPARE trial for the RSV vaccine. Other than the RSV vaccines in the pipeline, there is nothing else in the product pipeline in clinical trials apart from an Ebola vaccine and the need for this Ebola vaccine no longer has the same urgency because of the response of many countries to the earlier crisis. Even if the company developed an Ebola vaccine and secure the necessary approvals from the FDA and other global regulatory agencies, there is no assurance that this will produce enough revenue to result in a positive cash flow.

What the market and analysts think

The stock has been given a one-year price target of $ 3.58 and has a consensus recommendation of 2.67 on Zacks Investment Research on a scale showing 1 as a strong buy and 5 as a strong sell. On December 16, 2016, the company reported an EPS of – $ 0.21 per share compared to the analyst estimate of $ -0.23 per share and earnings surprise of 8.7%. For the current quarter, analysts expect the average EPS to be $ -0.16 per share, with a low of $ -0.18 per share and a high of $ -0.13 per share.

The company is expected to make its next earnings report in the first week of May 2017. Analysts have predicted average revenue estimates of 6.17 million with a low revenue estimate of 4 million and a high revenue estimate of 9 million. A year ago, the company had sales of 4.22 million. One analyst has rated the stock as a Strong Buy, one has given a Buy recommendation and seven have rated it as a Hold. When it comes to the price target, six analysts have reported that the price target might touch a high of $ 12, whereas the average price target is $ 3.58 and the low-price target is $ 1.5. The stock was downgraded on September 16, 2016, when Citigroup downgraded the stock from Buy to Neutral.

Source: Broad Street Alerts Editor

About Broad Street Alerts

Big Opportunities in Small Cap’s

Broad Street Alerts recent profiles and track record, 534% in verifiable potential gains for our members on 3 small cap alerts alone!

January 31^st, 2017- (NASDAQ: HIMX) opened at $5.10/share and hit a high of $9.68/share March 24^th, 2017 for gains of 89% within 60 days-

February 6th, 2017- (NASDAQ: SCON) opened at $1.12/share hit a high of $1.80/share within 10 days our member potential gains- 60% –

March 6th, 2017- (OTC: USRM) opened at .035/share and hit over .17/share within 25 days for gains of 385% for our members-

Hot sector, Golden cross chart. Technology for the Future of Healthcare (NASDAQ: VUZI)

Join Broad Street Alerts Facebook Group “Small Cap Breakout Stocks”

Why Should You Follow Broad Street Alerts?

Broad Street Alerts recent profiles in 2017 and track record, 534% in verifiable potential gains for our members on 3 small cap alerts alone!

What Happened to Valeant Pharmaceuticals?

Is There a Path to Profitability for Novavax

Privacy Policy and Disclaimer

Privacy Policy and Disclaimer

Your Consent

By using our site, you consent to our online privacy policy and disclaimer.

Do we disclose any information to outside parties?

We do not sell your information to anyone.

What information do we collect?

We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.

When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.

What do we use your information for?

When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.

Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason, other than our CRM providers for the express purpose of delivering the information on stocks that you requested.

We send periodic emails.

The email address you provide may be used to send you information, the small cap stock reports you requested, respond to inquiries, and/or other requests or questions.

How do we protect your information?

We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and SMS messages to you.

Because we value your privacy, we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act.

Online Privacy Policy Policy

This online privacy policy applies to information collected through our website and social media platforms.

Contacting Us

If there are any questions regarding this privacy policy or disclaimer you may reply to this email.

Disclaimer

BroadStreetAlerts. com is a wholly owned subsidiary of Small Cap Specialists LLC, herein referred to as SCS LLC.

Please Note: SCS LLC and its employees are not a registered investment advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.

SCS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.

SCS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. SCS LLC is not a Broker/Dealer and does not engage in high frequency trading.